Impact of PET on Intended Management for Initial Staging by Cancer Type*
| Cancer type | No. of scans | % of cases with change in management† | 95% CI | Imaging-adjusted impact (%)‡ | 95% CI |
|---|---|---|---|---|---|
| Prostate | 2,042 | 32.0 | 30.0–34.1 | 13.5 | 12.0–15.0 |
| Stomach | 1,556 | 40.5 | 38.0–42.9 | 14.8 | 13.1–16.6 |
| Pancreas | 1,491 | 39.2 | 36.8–41.7 | 13.4 | 11.7–15.1 |
| Bladder | 1,461 | 39.9 | 37.4–42.4 | 14.2 | 12.4–16.0 |
| Small cell lung | 1,082 | 43.3 | 40.4–46.3 | 8.1 | 6.5–9.8 |
| Kidney | 895 | 41.1 | 37.9–44.3 | 17.1 | 14.6–19.6 |
| Uterus | 746 | 41.6 | 38.0–45.1 | 14.1 | 11.6–16.6 |
| Liver and intrahepatic bile ducts | 607 | 44.2 | 40.2–48.1 | 14.3 | 11.5–17.1 |
| Connective tissue | 534 | 44.6 | 40.4–48.8 | 15.9 | 12.8–19.0 |
| Nonmelanoma skin | 526 | 37.5 | 33.3–41.6 | 10.1 | 7.5–12.6 |
| Gallbladder | 409 | 41.3 | 36.5–46.1 | 14.2 | 10.8–17.6 |
| Myeloma | 402 | 52.2 | 47.4–57.1 | 10.2 | 7.2–13.2 |
| Ovary | 378 | 43.1 | 38.1–48.1 | 16.1 | 12.4–19.8 |
| Cervix | 341 | 36.1 | 31.0–41.2 | 9.1 | 6.0–12.1 |
| Other female genital | 331 | 37.8 | 32.5–43.0 | 10.6 | 7.3–13.9 |
| All other | 1,564 | 40.4 | 38.0–42.8 | 13.4 | 11.7–15.1 |
| Total | 14,365 | 39.8 | 39.0–40.6 | 13.4 | 12.8–13.9 |